Warner Chilcott PLC, formerly Warner Chilcott Limited, is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceutical market. It is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of our products. The company has established strong franchises in women's healthcare and dermatology through its marketing techniques and specialty sales forces. It is an integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. Its operations are carried through its wholly-owned subsidiaries in the United States, Puerto Rico, the Republic of Ireland and Northern Ireland. The Companies franchises are comprised of complementary portfolios of established branded and development-stage products. The company is headquartered in Rockaway, New Jersey.
1 GRAND CANAL SQUARE DOCKLANDS DUBLIN 2 IRELAND, L2 00000, USA Phone: 35318972000 Web: http://www.wcrx.com Email: r@wcrx.com
Industry:MED-DRUGS Sector: Medical Fiscal Year End:December Last Reported Quarter:03/31/12 Next EPS Date:08/10/12
Capital Structure Solvency and Cash Flow
As of December 31, 2010, cash and cash equivalents amounted to $401.8 million versus $1.07 billion at the end of 3Q09 and $539.0 million as of December 31, 2009. Total debt outstanding was $4.7 billion at the end of 4Q10, comprising approximately $3.4 billion of term loans, $1.25 billion of 7.75% senior notes and $9.7 million of unamortized premium related to the 7.75% Notes.
In early January 2011, Warner Chilcott voluntarily prepaid $200 million under its senior secured credit facility. In March 2011, Warner Chilcott completed the refinancing of its prior senior secured credit facilities. The company utilized the proceeds of its term loan borrowings under its new $3.25 billion senior secured credit facilities, as well as approximately $279 million of cash on hand, to terminate its prior senior secured credit facilities and to pay related fees and expenses. One firm (Jefferies) believes that the lower interest rate due to the debt refinancing will boost 2011 adjusted earnings by $0.15.
Last edited Fri May 20, 2011 05:35 AM by gourabdas (Individual Investor)
Governance Social Responsibility and Employee Relations
In October 2010, Warner Chilcott bought the US rights to Novartis’ Enablex for $400 million and terminated its US co-promotion agreement with Novartis. Warner Chilcott expects to assume manufacturing control in the US within three years. Novartis retained rights to promote Enablex in all countries except the US.
Last edited Fri May 20, 2011 05:37 AM by gourabdas (Individual Investor)
The European patent of Actonel expired in late 2010. Generic threat looms over many other key franchises at Warner Chilcott. This will result in loss of revenues.
Last edited Fri May 20, 2011 05:38 AM by gourabdas (Individual Investor)
Created by: WikiMigrationBot.
Last Modification: Thursday 03 of June, 2010 09:08:24 CDT by WikiMigrationBot.
